First-line treatment of follicular lymphoma - A patient-oriented algorithm

Leukemia and Lymphoma

Volumn 50, Issue 3, 2009, Pages 325-334

  Feuerlein, Kristin ^a   Zucca, Emanuele ^a   Ghielmini, Michele ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Cure; Follicular lymphoma; Patient oriented algorithm; Prolonged remission; Prolonged survival; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BLEOMYCIN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; INTERFERON; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FOLLICULAR LYMPHOMA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTIOUS COMPLICATION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT; WATCHFUL WAITING; WHOLE BODY RADIATION;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DECISION TREES; HUMANS; LYMPHOMA, FOLLICULAR; QUALITY OF LIFE;

EID: 67650873367     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802713513     Document Type: Review

References (78)

1. Groves, F. D., Linet, M. A., Travis, L. B. and Devesa, S. S. (2000) Cancer surveillance series: Non Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst, 92, pp. 1240-1251.
2. Van Besien, K., Sobocinski, K. A., Rowlings, P. A., Murphy, S. C., Armitage, J. O. Bishop, M. R. et al. (1998) Allogenic bone marrow transplantation for low grade lymphoma. Blood, 92, pp. 1832-1836.
3. Tan, D., Rosenberg, S. A., Levy, R., Lavori, P., Tibshirani, R. Hoppe, R. T. et al. (2007) Survival in follicular lymphoma: The Stanford experience, 1960-2003. Blood (Suppl) (ASH Annual Meeting Abstracts), 110, p. 1005A.
4. Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M. and Miller, T. P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol, 23, pp. 8447-8452.
5. Liu, Q., Fayad, L., Cabanillas, F., Hagemeister, F. B., Ayers, G. D. Hess, M. et al. (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol, 24, pp. 1582-1589.
6. Zucca, E., Conconi, A., Motta, M., Wannesson, L., Gracia, E. Belisario, F. V. et al. (2007) Are we changing the survival of follicular lymphomas? Patterns of outcome in the patients treated at the oncology Institute of Southern Switzerland from 1979 to 2006. Eur J Cancer Suppl, 5, p. 346.
7. Sacchi, S., Pozzi, S., Marcheselli, L., Bari, A., Luminari, S. Angrilli, F. et al. (2007) Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer, 109, pp. 2077-2082.
8. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O. Arranz-Saez, R. et al. (2004) Follicular lymphoma international prognostic index. Blood, 104, pp. 1258-1265.
9. Swerdlow, S. H., Campo, E., Lee, H. N., Jaffe, E. S., Pileri, S. A. Stein, H. et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, pp. 222-223. Follicular Lymphoma, Lyon
10. Bartlett, N. L., Rizeq, M., Dorfmann, R. F., Halpern, J. and Horning, S. J. (1994) Follicular large-cell lymphoma: Intermediate or low grade?. J Clin Oncol, 12, pp. 1349-1357.
11. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. Vardiman, J. et al. (1999) World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 10, pp. 1419-1432.
12. Martin, A. R., Weisenburger, D. D., Chan, W. C., Ruby, E. I., Anderson, J. R. Vose, J. M. et al. (1995) Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood, 8, pp. 3671-3678.
13. Glas, A. M., Kersten, M. J., Delahaye, L. S., Witteveen, A. T., Kibbelaar, R. E. Velds, A. et al. (2005) Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood, 105, pp. 301-307.
14. Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D. Chan, W. C. et al. (2004) Predicition of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. A clinicopathologic study that identifies gene-expression signatures derived from FL biopsy specimens that predict for length of survival at time of initial diagnosis. N Engl J Med, 351, pp. 2159-2169.
15. Guadagnolo, B. A., Li, S., Neuberg, D., Ng, A., Hua, L. Silver, B. et al. (2006) Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys, 64, pp. 928-934.
16. Macmanus, M. P. and Hoppe, R. T. (1996) Is radiotherapy curative for stage one and two low-grade follicular lymphoma?. J Clin Oncol, 14, pp. 1282-1290.
17. Wilder, R. B., Jones, D., Tucker, S. L., Fuller, L. M., Ha, C. S. McLaughlin, P. et al. (2001) Long-term results in stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys, 51, pp. 1219-1227.
18. De Neve, W. J., Lybeert, M. L. and Meerwaldt, J. H. (1990) Low-dose total body irradiation in non-Hodgkin lymphoma: Short and long term toxicity and prognostic factor. Am J Clin Oncol, 13, pp. 280-284.
19. Lybeert, M. L., Meerwaldt, J. H. and De Neve, W. J. (1987) Long term results of low-dose total body irradiation for advanced non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys, 13, pp. 1167-1172.
20. Murtha, A., Rupnow, B., Hansosn, J., Knox, S. J. and Hoppe, R. (2001) Long-term follow-up of patients with III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phy, 49, pp. 3-15.
21. Van Besien, K., Loberiza, F. R., Bajorunaite, R., Armitage, J. O., Bashey, A. Burns, L. J. et al. (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 102, pp. 3521-3529.
22. Bierman, P. J., Sweetenham, J. W., Loberiza, F. R., Taghipour, G., Lazarus, H. M. Rizzo, J. D. et al. (2003) Syngeneic hematopoietic stem cell transplantation for non hodgkin lymphoma: A comparison with allogeneic and autologous transplantation. The Lymphoma Working Committee of the International Bone Marrow Transplant Reistry and the European Group for Blood and Marrow Transplantation. J Clin Oncol, 21, pp. 3744-3753.
23. Verdonck, L. F., Dekker, A. W., Lokhorst, H. M., Petersen, E. J. and Nieuwenhuis, H. K. (1997) Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non hodgkin's lymphoma. Blood, 90, pp. 4201-4205.
24. Van Besien, K. W., Khouri, I. F., Giralt, S. A., McCarthy, P., Mehra, R. Andersson, B. S. et al. (1995) Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol, 13, pp. 1096-1102.
25. Rohatiner, A. Z., Gregory, W. M., Peterson, B., Borden, E., Solal-Celigny, P. Hagenbeek, A. et al. (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol, 23, pp. 2215-2223.
26. Herold, M., Pasold, R., Srock, S., Neser, S., Niederwieser, D. Neubauer, A. et al. (2004) Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood, 104, p. 584.
27. Salles, G., Foussard, C., Nicolas, M., Franck, M., Chantal, D. Thierry, L. et al. (2004) Rituximab added to CHVP+IFN improves the outcome of follicular lymphoma patients: First analysis of the GELA-GOELAMS FL-2000 randomised trial. Blood, 4, p. 49.
28. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E. Catalano, J. et al. (2005) CVP chemotherapy polus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
29. Hiddenmann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E. Schmits, R. et al. (2005) Frontline therapy with Rituximab added to the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, pp. 3725-3732.
30. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A. Metzner, B. et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospectve randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, pp. 3064-3071.
31. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. Bouabdallah, R. et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
32. Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L. LoBuglio, A. F. et al. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol, 17, pp. 268-276.
33. Schulz, H., Skoetz, N., Bohlius, J., Trelle MD, S., Kober, T. Greb, A. et al. (2005) Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the teatment of patients with indolent non-hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis. Blood (Suppl)(ASH Annual Meeting Abstracts), 106
34. Zinzani, P. L., Pulsoni, A., Perrotti, A., Soverini, S., Zaja, F. De Renzo, A. et al. (2004) Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol, 22, pp. 2654-2661.
35. Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A. Raposo, J. C. et al. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol, 26, pp. 4579-4586.
36. Horning, S. J. and Rosenberg, S. A. (1984) The natural history of initially untreated low-grade non-Hodgkin lymphomas. N Engl J Med, 311, pp. 1471-1475.
37. (a) Brice, P, Bastion, Y., Lepage, E., Brousse, N., Haioun, C. Moreau, P. et al. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimstine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 15, pp. 1110-1117.
38. Advani, R., Rosenberg, S. A. and Horning, S. J. (2004) Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol, 22, pp. 1454-1459.
39. Ardenshna, K. M., Smith, P., Norton, A., Hancock, B. W., Hoskin, P. J. MacLennan, K. A. et al. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet, 362, pp. 516-522.
40. Montoto, S., Davies, A. J., Matthews, J., Calaminici, M., Norton, A. J. Amess, J. et al. (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol, 25, pp. 2426-2433.
41. Al-Tourah, A. J., Gill, K. K., Chhanabhai, M., Hoskins, P. J., Klasa, R. J. Savage, K. J. et al. (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin lymphoma. J Clin Oncol, 26, pp. 5165-5169.
42. van Oers, M. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E. Gascoyne, R. D. et al. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood, 108, pp. 3295-3301.
43. Galton, D. A., Israels, L. G., Nabarro, J. D. and Till, M. (1955) Clinical trial of p (dichloroethylamino) phenylbutyric acid (CB 1384) in malignant lymphoma. BMJ, 2, pp. 1172-1176.
44. Johnson, P WM, Rohatiner, A ZS, Whelan, J. S., Price, C GA, Love, S. Jim, J. et al. (1995) Patterns of Survival I patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol, 13, pp. 140-147.
45. Peterson, B. A., Petroni, G. R., Frizzera, G., Barcos, M., Bloomfield, C. D. Nissen, N. I. et al. (2003) Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the cancer and leukemia group B. J Clin Oncol, 21, pp. 5-15.
46. Leone, G., Voso, M. T., Sica, S., Morosetti, R. and Pagano, L. (2001) Therapy related leukemias: Susceptibility, prevention and treatment. Leuk Lymphoma, 41, pp. 255-276.
47. Larson, R. A. and Le Beau, M M (2005) Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact, 153, pp. 187-195.
48. Bremer, K. (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol, 128, pp. 603-609.
49. Hagenbeek, A., Eghbali, H., Monfardini, S., Vitolo, U., Hoskin, P. J. de Wolf-Peeters, C. et al. (2006) Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol, 24, pp. 1590-1596.
50. Saven, A., Emanuele, S., Kosty, M., Koziol, J., Ellison, D. and Piro, L. (1995) 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood, 86, pp. 1710-1716.
51. Betticher, D. C., Zucca, E., von Rohr, A., Egger, T., Radford, J. A. Ambrosetti, A. et al. (1996) 2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol, 7, pp. 793-799.
52. Colombat, P., Brousse, N., Morschhauser, F., Franchi-Rezgui, P., Soubeyran, P. Delwail, V. et al. (2006) Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma: Survival analyses with extended follow-up of 7 years. Blood (ASH Annual Meeting Abstracts), 108
53. Ghielmini, M., Rufibach, K., Salles, G., Leoncini-Franscini, L., Leger-Falandry, C. Cogliatti, S. et al. (2005) Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol, 16, pp. 1675-1682.
54. Ghielmini, M., Schmitz, S. F., Cogliatti, S. B., Pichert, G., Hummerjohann, J. Waltzer, U. et al. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule (SAKK 35/98). Blood, 103, pp. 4416-4423.
55. Martinelli, G., Laszlo, D., Bertolini, F., Pastano, R., Mancuso, P. Calleri, A. et al. (2003) Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's Lymphoma. Br J Haematol, 123, pp. 21-27.
56. Rummel, M. J., Al-Batran, S. E., Kim, S. Z., Welslau, M., Hecker, R. Kofahl-Krause, D. et al. (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin's lymphoma. J Clin Oncol, 23, pp. 3383-3389.
57. Czuczman, M. S., Koryzna, A., Mohr, A., Stewart, C., Donohue, K. Blumenson, L. et al. (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol, 23, pp. 694-704.
58. Rummel, M. J., von Grunhagen, U., Niederle, N., Rothmann, F., Ballo, H. Weidmann, E. et al. (2007) On behalf of the StiL. Bendamustin plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas-first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (Suppl) (ASH Annual Meeting Abstracts), 110
59. Robak, T., Smolewski, P., Cebula, B., Szmigielska-Kaplon, A., Chojnowski, K. and Blonski, J. Z. (2006) Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer, 107, pp. 1542-1550.
60. Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W. Zasadny, K. et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 352, pp. 441-449.
61. Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, C., Raubtischek, A. Darif, M. et al. (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase I/II study. Blood, 103, pp. 4429-4431.
62. Nickenig, C., Dreyling, M., Hoster, E., Pfreundschuh, M., Trumper, L. Reiser, M. et al. (2006) Combined Cyclophosphamide, Vincistine, Doxirubicin and Prednisone (CHOP) improves response rates but not survivial and has lower hematologic toxicity compared with combined Mitoxantrone, Chlorambucil and Prednisone (MCP) in follicular and mantle cell lymphomas. Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer, 107, pp. 1014-1022.
63. Flinn, I. W., Byrd, J. C., Morrison, C., Jamison, J., Diehl, L. F. Murphy, T. et al. (2000) Fludarabine and cyclophosphamied with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood, 96, pp. 71-75.
64. Lopez-Guillermo, A., Montserrat, E., Bosch, F., Escoda, L., Terol, M. J. Marin, P. et al. (1994) Low-grade lymphoma: Clinical and prognostic studies in a series of 143 patients from a single institution. Leuk Lymphoma, 15, pp. 159-165.
65. Peterson, B. A., Petroni, G. R., Frizzera, G., Barcos, M., Bloomfield, C. D. Nissen, N. I. et al. (2003) Prolonged single agent versus combination chemotherapy in indolent follicular lymphomas: A study of the cancer and leukaemia group B. J Clin Oncol, 21, pp. 5-15.
66. Longo, D. L., Soung, R. C., Hubbard, S. M., Wesley, M., Fisher, R. I. Jaffe, E. et al. (1984) Prolonged initial remission in patient with nodular mixed lymphoma. Ann Intern Med, 100, pp. 651-656.
67. Rigacci, L., Federico, M., Martelli, M., Zinzani, P. L., Cavanna, L. Bellesi, G. et al. (2003) The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma, 44, pp. 1911-1917.
68. Glick, J. H., Barnes, J. M., Ezdinli, E. Z., Berard, C. W., Orlow, E. L. and Bennett, J. M. (1981) Nodular mixed lymphoma: Results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood, 58, pp. 920-925.
69. Tse, W. W., Lazarus, H. M. and Van Besien, K. (2004) Stem cell transplantation in follicular lymphoma: Progress at last? Comprehensive review of the role of autologous and allogenic stem cell transplantation in FL including issues regarding purging and reduced intensity conditioning. Bone Marrow Transplant, 34, pp. 929-938.
70. Lenz, G., Dreyling, M., Schiegnitz, E., Forstpointner, R., Wandt, H. Freund, M. et al. (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in Lymphoma Study Group. Blood, 104, pp. 2667-2674.
71. Deconinck, E., Foussard, C., Milpied, N., Bertrand, P., Michenet, P. Cornillet-LeFebvre, P. et al. (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GEOLAMS. Blood, 105, pp. 3817-3823.
72. Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P. Haioun, C. et al. (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood, 108, pp. 2540-2544.
73. Lenz, G., Dreyling, M., Schiegnitz, E., Haferlach, T., Hasford, J. Unterhalt, M. et al. (2004) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol, 22, pp. 4926-4933.
74. Ladetto, M., De Marco, F., Benedetti, F., Vitolo, U., Patti, C. Rambaldi, A. et al. (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage. Blood, 111, pp. 4004-4013.
75. Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Manuel Grimaldi, M and Anthony Greco, A F (2005) Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol, 23, pp. 1088-1095.
76. Howard, S. H., Edie, W., Randy, D. G., Teresa, S. R., Thomas, M. H. Leo, I. G. et al. (2005) Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (Suppl) (ASH Annual Meeting Abstracts), 106, p. 349.
77. Kimby, E., Jurlander, J., Geisler, C., Hagberg, H., Holte, H. Lehtinen, T. et al. (2008) Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma, 49, pp. 102-112.
78. Hagenbeek, A., Bischof-Delaloye, B., Radford, J. A., Rohatiner, A., Salles, G. Van Hoof, A. et al. (2007) 90Y-Ibritumomab Tiuxetan (Zevalin) consolidation of first remission in advanced stage follicular non-hodgkin's lymphoma: First results of the international randomized phase 3 first-line indolent trial (FIT) in 414 patients. Blood (ASH Annual Meeting Abstracts), 110